Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat 1993 May;7(1):79-84
Date
05/01/1993Pubmed ID
8395256Scopus ID
2-s2.0-0027210498 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Hyperacute rejection is a serious complication of xenogeneic organ transplantation. It is believed that platelets play a pivotal role in this phenomenon. In this study, we provide the first known evidence of the efficacy of the PAF receptor antagonist, tulopafant, in improvement in graft function and histology of discordant cardiac xenografts. Transplantation of guinea pig hearts into recipient rats resulted in hyperacute rejection. Pretreatment of recipient animals with tulopafant (but not indomethacin) extended rejection time by 4-5-fold. Histological examination revealed marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals were pretreated with tulopafant.
Author List
O'Hair DP, Roza AM, Komorowski R, Moore G, McManus RP, Johnson CP, Adams MB, Pieper GMAuthor
Christopher P. Johnson MD Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCapillaries
Graft Survival
Guinea Pigs
Heart Transplantation
Male
Platelet Membrane Glycoproteins
Pyridines
Rats
Rats, Inbred Lew
Receptors, Cell Surface
Receptors, G-Protein-Coupled
Thiazoles
Time Factors
Transplantation, Heterologous
Vascular Patency
